Clinical Trial Protocol Template

---
title: "Clinical Trial Protocol Template"
methodology: "universal"
complexity: "advanced"
owner: "mirichard"
updated: "2026-09-19"
primary_principles: ["stewardship", "quality-by-design"]
secondary_principles: ["evidence-based-decisions"]
principle_rationale: "Connects study objectives, endpoints and safety responsibilities to a protocol that qualified scientific and ethics reviewers can evaluate."
---

# Clinical Trial Protocol Template

## When to Use

- When a clinical research team drafts a protocol for qualified scientific and ethics review.
- When objectives, endpoints, study population, and safety responsibilities need a coherent design.

## When NOT to Use

- To initiate participant recruitment or procedures without the required approvals.
- Do not represent author self-checks as independent or authorized approval. See [Self-approval](../../../../../docs/principles/anti-patterns.md#self-approval).

## Pairs Well With

- [Health Authority Communication Plan Template](../../../../../domains/delivery/industry-specializations/healthcare-pharmaceutical/regulatory/health_authority_communication_plan_template.md).
- [Regulatory Strategy Plan Template](../../../../../domains/delivery/industry-specializations/healthcare-pharmaceutical/regulatory/regulatory_strategy_plan_template.md).

Selection context: Delivery domain; universal methodology; advanced complexity. Match the situations above to project phase, risk, team size, and industry using the [decision-engine context model](../../../../../meta/architecture-research/800-801-context-assessment-model.md).

Reference check: [Current source](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r3-good-clinical-practice-gcp).


## Applying this template

Treat filled examples, dates, numerical limits, sampling frequencies, and approval outcomes as illustrations. Before execution, replace them with the approved product/site requirements, scientific rationale, method references, responsible reviewer, and acceptance evidence. Record the applicable jurisdiction and current guidance edition; a completed worksheet alone does not demonstrate regulatory compliance.

| Requirement or limit | Applicable source / edition | Product-specific rationale | Approval / date | Execution evidence |
|---|---|---|---|---|
| [Requirement] | [Source] | [Rationale] | [Reviewer / date] | [Record] |


This is a protocol-planning worksheet. Map the study to applicable ICH E6(R3) guidance and local requirements, including critical-to-quality factors, participant protection, proportionate risk controls, and sponsor/investigator responsibilities. Protocol approval and compliance require study-specific evidence.

## Document Control

| Document Information | Details |
|---------------------|---------|
| Protocol Title      | [TITLE OF THE CLINICAL TRIAL] |
| Protocol Number     | [UNIQUE IDENTIFIER] |
| Protocol Version    | [VERSION NUMBER] |
| Date of Protocol    | [DATE] |
| Sponsor             | [SPONSOR NAME AND ADDRESS] |
| Principal Investigator | [NAME AND AFFILIATION] |
| Medical Monitor     | [NAME AND CONTACT INFORMATION] |
| Amendment History   | [TABLE OF AMENDMENTS, DATES, AND BRIEF DESCRIPTIONS] |

---

## 1. Protocol Summary and Administrative Information

### 1.1 Synopsis

| Element | Description |
|---------|-------------|
| Title | [Full title of the clinical trial] |
| Phase | [Phase of clinical development (e.g., I, II, III, IV)] |
| Study Design | [Brief description of study design, e.g., "Randomized, double-blind, placebo-controlled, parallel-group study"] |
| Study Population | [Brief description of the target population] |
| Planned Sample Size | [Number of subjects to be enrolled] |
| Study Duration | [Expected duration of subject participation and overall study timeline] |
| Primary Objective | [Primary objective of the study] |
| Primary Endpoint | [Primary endpoint measurement] |
| Key Secondary Objectives | [List of key secondary objectives] |
| Key Secondary Endpoints | [List of key secondary endpoints] |
| Investigational Product | [Name, dose, route, regimen] |

### 1.2 Schedule of Assessments

[INSERT TABLE: Comprehensive timeline of all study procedures and assessments across visits]

### 1.3 List of Abbreviations

[INSERT TABLE: Alphabetical list of all abbreviations used in the protocol with their definitions]

### 1.4 Protocol Signature Page

[Space for signatures of Principal Investigator, Sponsor Representative, and other key stakeholders confirming agreement to conduct the study according to the protocol]

---

## 2. Background and Rationale

### 2.1 Background Information

[Provide relevant background information on the disease/condition being studied, including epidemiology, current treatment options, and unmet medical needs]

### 2.2 Preclinical Experience

[Summarize relevant preclinical data that supports the clinical investigation, including pharmacology, toxicology, and other relevant non-clinical studies]

### 2.3 Clinical Experience

[Summarize relevant previous clinical experience with the investigational product, including completed and ongoing studies, if applicable]

### 2.4 Study Rationale

[Explain the scientific rationale for conducting the study, including the risk/benefit assessment and how the study will address scientific questions or unmet medical needs]

### 2.5 Dose Rationale

[Provide justification for the dose(s) selected for investigation, including dose-ranging considerations if applicable]

### 2.6 Risk/Benefit Assessment

[Discuss potential risks and benefits to trial participants, including risk mitigation strategies]

---

## 3. Trial Objectives and Endpoints

### 3.1 Primary Objective

[Clearly state the primary objective of the clinical trial]

### 3.2 Primary Endpoint(s)

[Define the primary endpoint(s) that will be used to assess the primary objective, including specific measurement methods and timing]

### 3.3 Secondary Objectives

[List all secondary objectives of the clinical trial]

### 3.4 Secondary Endpoints

[Define all secondary endpoints that will be used to assess the secondary objectives, including specific measurement methods and timing]

### 3.5 Exploratory Objectives (if applicable)

[List any exploratory objectives of the clinical trial]

### 3.6 Exploratory Endpoints (if applicable)

[Define any exploratory endpoints, including specific measurement methods and timing]

---

## 4. Trial Design

### 4.1 Overall Design and Plan

[Provide a detailed description of the trial design, including a schematic diagram of trial design, procedures, and stages]

### 4.2 Scientific Rationale for Trial Design

[Explain the rationale for the chosen trial design elements, including control groups, randomization, blinding, etc.]

### 4.3 Randomization and Blinding

#### 4.3.1 Randomization Method

[Describe the randomization procedure, including stratification factors if applicable]

#### 4.3.2 Blinding Procedures

[Describe methods for maintaining the blind, including packaging and labeling of investigational products]

#### 4.3.3 Unblinding Procedures

[Describe circumstances and procedures for emergency unblinding]

### 4.4 Study Duration

[Specify the expected duration of subject participation, description of study stages/periods, and the overall study timeline]

---

## 5. Study Population (Selection and Withdrawal)

### 5.1 Target Population

[Describe the general characteristics of the target population]

### 5.2 Inclusion Criteria

[List all inclusion criteria that subjects must meet to be eligible for the study]

### 5.3 Exclusion Criteria

[List all exclusion criteria that would prevent subjects from participating in the study]

### 5.4 Screening Failures

[Define how screening failures will be handled and documented]

### 5.5 Withdrawal/Discontinuation Criteria

#### 5.5.1 Reasons for Withdrawal/Discontinuation

[List all potential reasons for withdrawal or discontinuation from the study]

#### 5.5.2 Handling of Withdrawals

[Describe procedures for handling subject withdrawals, including follow-up requirements]

#### 5.5.3 Replacement Policy

[Specify whether and how withdrawn subjects will be replaced]

### 5.6 Subject Identification and Enrollment

[Describe procedures for identifying and enrolling subjects, including the informed consent process]

---

## 6. Treatment/Intervention

### 6.1 Investigational Product(s)

#### 6.1.1 Description

[Provide detailed description of the investigational product(s), including formulation, packaging, and labeling]

#### 6.1.2 Dosage and Administration

[Describe the dosage regimen and administration procedures]

#### 6.1.3 Dose Modifications

[Specify criteria and procedures for dose modifications or adjustments]

### 6.2 Control/Comparator (if applicable)

[Provide detailed description of any control or comparator products]

### 6.3 Concomitant Medications

#### 6.3.1 Permitted Medications

[List medications allowed during the study period]

#### 6.3.2 Prohibited Medications

[List medications not allowed during the study period]

### 6.4 Treatment Compliance

[Describe methods for monitoring and ensuring treatment compliance]

### 6.5 Investigational Product Accountability

[Describe procedures for receiving, storing, dispensing, and reconciling investigational products]

---

## 7. Safety Assessment and Reporting

### 7.1 Safety Parameters

#### 7.1.1 Vital Signs

[Specify vital sign measurements and assessment schedule]

#### 7.1.2 Physical Examinations

[Describe the scope and frequency of physical examinations]

#### 7.1.3 Laboratory Assessments

[List all laboratory tests to be performed and assessment schedule]

#### 7.1.4 Other Safety Assessments

[Describe any other safety assessments, e.g., ECG, imaging, etc.]

### 7.2 Adverse Events

#### 7.2.1 Definitions

[Provide definitions of adverse events (AEs) and serious adverse events (SAEs)]

#### 7.2.2 Assessment and Documentation

[Describe procedures for assessing and documenting AEs, including severity and causality assessment]

#### 7.2.3 Reporting Requirements

[Specify reporting requirements for AEs and SAEs, including timeframes and procedures]

### 7.3 Pregnancy

[Describe procedures for handling and reporting pregnancies during the study]

### 7.4 Data Monitoring Committee (if applicable)

[Describe the composition, role, and responsibilities of the Data Monitoring Committee]

---

## 8. Data Collection and Management

### 8.1 Source Documents

[Define source documents and data to be directly recorded in the CRF]

### 8.2 Case Report Forms

[Describe the CRF system to be used (electronic or paper) and procedures for completion and review]

### 8.3 Data Management

[Describe data management procedures, including data entry, validation, and query resolution]

### 8.4 Quality Control and Quality Assurance

[Describe quality control and quality assurance procedures for the study]

### 8.5 Records Retention

[Specify record retention requirements and procedures]

### 8.6 Monitoring

[Describe monitoring procedures, including frequency and scope of monitoring visits]

---

## 9. Statistical Methods

### 9.1 Statistical Design

[Describe the overall statistical design and analysis plan]

### 9.2 Sample Size Determination

[Provide justification for the planned sample size, including assumptions and calculations]

### 9.3 Analysis Populations

[Define analysis populations (e.g., intent-to-treat, per-protocol, safety population)]

### 9.4 Statistical Analysis

#### 9.4.1 Primary Endpoint Analysis

[Describe the statistical methods for analyzing the primary endpoint(s)]

#### 9.4.2 Secondary Endpoint Analysis

[Describe the statistical methods for analyzing secondary endpoints]

#### 9.4.3 Exploratory Analysis (if applicable)

[Describe the statistical methods for exploratory analyses]

#### 9.4.4 Safety Analysis

[Describe the methods for analyzing safety data]

### 9.5 Interim Analysis (if applicable)

[Describe any planned interim analyses, including stopping rules and adjusted significance levels]

### 9.6 Handling of Missing Data

[Describe methods for handling missing data in the analyses]

---

## 10. Quality Control and Assurance

### 10.1 Data Quality Control

[Describe procedures to ensure data quality, including data validation processes]

### 10.2 Study Monitoring

[Describe monitoring procedures to ensure protocol compliance and data quality]

### 10.3 Audits and Inspections

[Describe procedures for audits and inspections]

### 10.4 Protocol Deviations

[Define protocol deviations and procedures for documenting and reporting them]

---

## 11. Ethical Considerations

### 11.1 Regulatory and Ethical Compliance

[State the commitment to conduct the study in compliance with applicable regulations and ethical principles]

### 11.2 Institutional Review Board/Independent Ethics Committee

[Describe procedures for IRB/IEC review and approval]

### 11.3 Informed Consent Process

[Describe the informed consent process, including procedures for obtaining informed consent]

### 11.4 Subject Confidentiality

[Describe measures to protect subject confidentiality]

### 11.5 Compensation for Study Participation

[Describe any compensation or reimbursement to be provided to subjects]

### 11.6 Study Discontinuation

[Describe criteria and procedures for premature termination of the entire study]

---

## 12. Administrative Procedures

### 12.1 Protocol Amendments

[Describe procedures for making and implementing protocol amendments]

### 12.2 Protocol Deviations

[Describe procedures for handling and reporting protocol deviations]

### 12.3 Publication Policy

[Describe the publication policy for study results]

### 12.4 Clinical Study Report

[Describe plans and timeline for the clinical study report]

### 12.5 Study Administrative Structure

[Provide an overview of the administrative structure for the study, including key roles and responsibilities]

---

## 13. References and Appendices

### 13.1 References

[List all references cited in the protocol using a consistent citation format]

### 13.2 Appendices

#### Appendix A: Schedule of Assessments

[Detailed table of all study procedures by visit]

#### Appendix B: Laboratory Tests

[Comprehensive list of all laboratory tests with reference ranges]

#### Appendix C: Pharmacokinetic Sampling (if applicable)

[Detailed schedule and procedures for PK sampling]

#### Appendix D: Clinical Trial Governance Structure

[Organizational chart showing relationships between sponsor, investigators, and committees]

#### Appendix E: Investigational Product Information

[Additional details about the investigational product, including chemistry, manufacturing, and controls information as appropriate]

#### Appendix F: Assessment Scales and Questionnaires

[Copies of any scales or questionnaires to be used in the study]

#### Appendix G: Algorithm for Subject Discontinuation

[Flowchart or decision tree for subject discontinuation scenarios]

---

## Implementation Notes

- This template should be customized for each specific clinical trial protocol
- Sections may be added, removed, or modified based on specific trial requirements
- All instructions and bracketed placeholder text should be replaced with study-specific information
- The protocol should be reviewed by all relevant stakeholders before finalization
- Version control should be maintained for all protocol versions and amendments

---

*Template Version: 1.0 | Last Updated: [DATE]*